Literature DB >> 6988108

Prevalence of precipitins in groups at risk of developing hypersensitivity pneumonitis.

G H Scribner, J J Barboriak, J N Fink.   

Abstract

A study was made of the prevalence of serum precipitins to Micropolyspora faeni, Thermoactinomyces vulgaris, Aspergillus fumigatus, and pigeon serum in population groups suspected to be at high risk for the development of hypersensitivity pneumonitis. Pigeon breeders' sera contained precipitins mainly to pigeon serum (38%) and A. fumigatus (18%). Occupants of homes in which forced air heating systems were investigated for the presence of microorganisms reacted mostly with M. faeni (13%) and A. fumigatus (8%). Individuals from environments where several cases of hypersensitivity pneumonitis were discovered reacted largely with M. faeni (28%) and T. vulgaris (21%). Sera supplied by physicians from patients with respiratory symptoms reacted primarily to A. fumigatus (24%) and to a lesser extent to M. faeni (16%) and T. vulgaris (9%). The results indicate that the prevalence of precipitins to the tested antigens is not uniform and may be influenced by the environment. Furthermore, the prevalence of precipitins in groups at risk is greater than previously reported for the normal population.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6988108     DOI: 10.1111/j.1365-2222.1980.tb02084.x

Source DB:  PubMed          Journal:  Clin Allergy        ISSN: 0009-9090


  2 in total

1.  Immune responsiveness to inhaled antigens: local antibody production in the respiratory tract in health and lung diseases.

Authors:  Y Yoshizawa; Y Ohtani; T Inoue; S Miyake; A Ikeda; M Tanba; V P Kurup
Journal:  Clin Exp Immunol       Date:  1995-06       Impact factor: 4.330

Review 2.  Challenges in the Diagnosis and Management of Fibrotic Hypersensitivity Pneumonitis: A Practical Review of Current Approaches.

Authors:  Teng Moua; Tananchai Petnak; Antonios Charokopos; Misbah Baqir; Jay H Ryu
Journal:  J Clin Med       Date:  2022-03-08       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.